Home > Insider Trading > Filing (0001415889-23-003064)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1800	Abbott Laboratories	ABT	Pharmaceutical Preparations (2834)	360698440

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1867573	L. Julie Tyler	100 Abbott Park Road Abbott Park IL 60064	Senior Vice President	No	No	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Shares Without Par Value	Acquisiton	2023-02-17	7,920	$0.00	41,788	No	4	A	Direct
Common Shares Without Par Value	Disposition	2023-02-19	291	$106.74	41,497	No	4	F	Direct
Common Shares Without Par Value	Disposition	2023-02-21	341	$106.74	41,156	No	4	F	Direct
Common Shares Without Par Value	Disposition	2023-02-22	260	$103.24	40,896	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	A	Direct
No	4	F	Direct
No	4	F	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Shares	Option (right to buy)	Acquisiton	2023-02-17	31,236	$0.00	31,236	$106.24

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
31,236	2024-02-17	2033-02-16	No	4	A	Direct

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Shares Without Par Value	9,513	Indirect	Profit Sharing Trust

Footnotes

These shares represent a performance-based restricted stock award under the Abbott Laboratories 2017 Incentive Stock Program. The award has a 3-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The award includes the right to have shares withheld for tax purposes.
Balance in the Abbott Laboratories Stock Retirement Trust as of February 17, 2023.
Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 10,412 on February 17, 2024, 10,412 on February 17, 2025 and 10,412 on February 17, 2026.